GlaxoSmithKline: Influenza, Human trials

The registry lists 187 Influenza, Human studies with GlaxoSmithKline as lead sponsor. 3 are open to participants now and 132 have results posted.

Phase 1 25Phase 2 56Phase 3 74Phase 4 12No phase 23(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of AgeRecruitingNCT07851246Phase 3
• A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of AgeRecruitingNCT07805707Phase 3
• A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in AdultsRecruitingNCT07464314Phase 1
• A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older AdultsCompletedNCT06431607Phase 2Results posted
• Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable AdultsCompletedNCT05975840Phase 1/2Results posted
• A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older AdultsCompletedNCT05823974Phase 1/2Results posted
• A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in IndiaCompletedNCT05648357Phase 4Results posted
• A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older AdultsCompletedNCT05446740Phase 1Results posted
• A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster VaccineCompletedNCT05047770Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and OlderCompletedNCT04789577Phase 2Results posted
• Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza SeasonCompletedNCT03688620Phase 4Results posted
• Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in EnglandCompletedNCT03278067Results posted
• A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 YearsCompletedNCT03275389Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With InfluenzaTerminatedNCT02927431Phase 2Results posted
• Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza VaccinesCompletedNCT02893878Results posted
• Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015CompletedNCT02885246Results posted
• A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of AgeCompletedNCT02719743Phase 2Results posted
• Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.CompletedNCT02663102Results posted
• Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and AboveCompletedNCT02369341Phase 3Results posted
• Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of AgeCompletedNCT02242643Phase 3Results posted
• Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and OlderCompletedNCT02218697Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and ChildrenCompletedNCT02207413Phase 3Results posted
• Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy RegistryCompletedNCT02148211Results posted
• Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of AgeCompletedNCT01974895Phase 2Results posted
• Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and OlderCompletedNCT01949090Phase 2Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and OlderCompletedNCT01884519Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and OlderCompletedNCT01878825Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and OlderCompletedNCT01878812Phase 3Results posted
• Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) ExposureCompletedNCT01788228Phase 3Results posted
• Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years OldCompletedNCT01730378Phase 4Results posted
• Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of AgeCompletedNCT01711736Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345CompletedNCT01702454Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in AdultsCompletedNCT01626820Phase 3Results posted
• A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and AboveCompletedNCT01607112Phase 3Results posted
• Study on the Burden of Influenza-related Hospitalizations and Emergency Room (ER) Visits in Children in SpainCompletedNCT01592799Not applicableResults posted
• A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza InfectionCompletedNCT01527110Phase 3Results posted
• A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and OlderCompletedNCT01440387Phase 3Results posted
• An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in ChildrenCompletedNCT01439360Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in AdultsCompletedNCT01416571Phase 2Results posted
• A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in ChildrenCompletedNCT01379937Phase 3Results posted
• A Comparison of Solid and Soluble Forms of Cold and Influenza RemediesCompletedNCT01332578Phase 4Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in ChildrenCompletedNCT01323946Phase 2Results posted
• Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of AgeCompletedNCT01310413Phase 3Results posted
• A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With InfluenzaCompletedNCT01231620Phase 3Results posted
• A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in ChildrenCompletedNCT01218308Phase 3Results posted
• Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)CompletedNCT01204671Phase 3Results posted
• Relenza® Sentinel Site Monitoring Program in JapanCompletedNCT01199744Results posted
• A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in ChildrenCompletedNCT01198756Phase 3Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in ChildrenCompletedNCT01196988Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in AdultsCompletedNCT01196975Phase 3Results posted
• Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™CompletedNCT01196026Phase 4Results posted
• Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy ChildrenTerminatedNCT01195779Phase 2Results posted
• Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTMCompletedNCT01190215Phase 4Results posted
• Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years OldCompletedNCT01161160Phase 2Results posted
• Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TMTerminatedNCT01160237Phase 3Results posted
• Prophylactic Efficacy of Relenza Against Influenza A and BCompletedNCT01156701Results posted
• Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 YearsCompletedNCT01153685Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in AdultsCompletedNCT01144299Phase 3Results posted
• Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or OlderCompletedNCT01114620Phase 4Results posted
• Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy ChildrenCompletedNCT01096056Phase 1Results posted
• Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in AdultsCompletedNCT01059617Phase 1Results posted
• Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of AgeCompletedNCT01051661Phase 3Results posted
• Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 YearsCompletedNCT01035749Phase 2Results posted
• Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in HospitalCompletedNCT01014988Phase 2Results posted
• Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in ChildrenTerminatedNCT01014091Phase 3Results posted
• Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in ChildrenTerminatedNCT01003418Phase 2Results posted
• Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese ChildrenCompletedNCT01001169Phase 2Results posted
• Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly PeopleCompletedNCT00992784Phase 3Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing ProcessesCompletedNCT00992511Phase 3Results posted
• Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)CompletedNCT00989612Phase 2Results posted
• Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in AdultsCompletedNCT00989287Phase 3Results posted
• Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy ChildrenCompletedNCT00985790Phase 2Results posted
• Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in AdultsCompletedNCT00985673Phase 2Results posted
• Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and OlderCompletedNCT00985088Phase 2Results posted
• Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in ChildrenCompletedNCT00980005Phase 3Results posted
• Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and OlderCompletedNCT00979602Phase 3Results posted
• Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)CompletedNCT00979407Phase 3Results posted
• Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of AgeCompletedNCT00976820Phase 2Results posted
• Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in AdultsCompletedNCT00975884Phase 3Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in ChildrenCompletedNCT00972517Phase 3Results posted
• Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)CompletedNCT00971425Phase 3Results posted
• Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)CompletedNCT00971321Phase 2Results posted
• Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in ElderlyCompletedNCT00968890Phase 2Results posted
• Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in AdultsCompletedNCT00968539Phase 3Results posted
• Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in AdultsCompletedNCT00968526Phase 3Results posted
• Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)CompletedNCT00964158Phase 3Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in AdultsCompletedNCT00951041Phase 2Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the ElderlyCompletedNCT00938392Phase 3Results posted
• Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 YearsCompletedNCT00929331Phase 3Results posted
• A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in AdultsCompletedNCT00920374Phase 3Results posted
• A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.CompletedNCT00812981Phase 3Results posted
• Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the ControlCompletedNCT00778895Phase 2Results posted
• Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the ElderlyCompletedNCT00772889Phase 3Results posted
• Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 YearsCompletedNCT00771615Phase 2Results posted
• Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or OlderCompletedNCT00765076Phase 3Results posted
• Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in ChildrenCompletedNCT00764790Phase 3Results posted
• Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and OlderCompletedNCT00760617Phase 3Results posted
• Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and OlderCompletedNCT00753272Phase 3Results posted
• Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.CompletedNCT00750360Phase 4Results posted
• Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate VaccineCompletedNCT00742885Phase 2Results posted